Category : Healthcare and Pharmaceuticals | Published at : January-2019 | Delivery Format : PDF | Status: Published | Pages : 160
Introduction
The global brachytherapy market size is expected to around USD 454.3 billion by 2026, this market is foreseen to develop with 5.1% CAGR during the forecast time period.
Market Dynamics
Technological advancements and R&D speculations by key market players are a some of the real development drivers. In August 2017, Salutaris Medical Devices propelled the preliminary of brachytherapy treatment for neovascular age-related macular degeneration. The preliminary is to think about specialists' simplicity in utilizing SalutarisMD framework (SMD-DA framework) alongside the counter VEGF treatment routine and the security of the equivalent.
Market Insights
As indicated by the International Agency for Research on Cancer, in 2015, in excess of 15 million individuals experienced cancer growth while 8.8 million passings were caused by the malady around the world. This number is relied upon to ascend to 24 million by 2035. It is additionally evaluated that 23.6 million new malignancy cases will be analyzed by 2030.
As per the American Brachytherapy Society, security, and viability of brachytherapy treatment over other cancer growth medicines, for example, chemotherapy and medical procedure, is relied upon to help the market. Likewise, good repayment rules are relied upon to add to the rising appropriation of brachytherapy.
The Center for Medicare and Medicaid (CMS) executed new High-Dose Rate (HDR) treatment conveyance codes in 2016. The last rates for 2017 incorporated an expansion of around 5% to 6% in installments. Expanding utilization of these advancements and the nearness of good repayment approaches in creating nations are required to additionally fuel development of the brachytherapy market.
Market Segmentation
Market By Type
- High Dose Rate (HDR)
- Low Dose Rate (HDR)
Market By Application
- Prostate Cancer
- Gynecological Cancer
- Breast Cancer
- Others
Market By Geography
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- Rest of Asia-Pacific
- Latin America
- Brazil
- Chile
- Rest of Latin America
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- Rest of MEA
Regional Insights
North America held the largest market of the overall industry in 2018. Brachytherapy is broadly utilized in North America because of the points of demand it offers over conventional strategies as it is similarly more secure and proficient cancer growth treatment. As indicated by the American Cancer Society, in 2018, in excess of 2 million new cancer growth cases will be analysed in U.S. The healthcare changes in U.S. have enhanced access and inclusion for the populace and they go for expanding effectiveness of the health care system.
In Europe, the EU Science Hub has evaluated that the quantity of new disease cases in the region are foreseen to increment quickly because of statistic changes. Radiotherapy is required to be the most favoured treatment alternative in such cases. As indicated by the EU Science Hub, by 2018 there will be 3.9 million new cases and more than 1.9 million passing because of cancer in Europe. Also, radiotherapy is imperative for viable treatment of larger part of tumours in center and low-pay nations. These elements are foreseen to look good for the development of the market for brachytherapy in not so distant future.
Asia Pacific Brachytherapy market is ready to witness the most noteworthy CAGR amid the coming years from 2018 to 2025. The area represents over 60% of total populace and a large portion of the worldwide burden of cancer.
Market Participants
Few of the main player present in the global Brachytherapy market are Varian Medical Systems, Inc.; Eckert & Ziegler BEBIG; Elekta AB; and IsoRay Medical, Inc.
